Analysts Anticipate SenesTech Inc (SNES) to Announce ($0.11) Earnings Per Share

SenesTech Inc (NASDAQ:SNES) has been given a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.

Brokers have set a 12 month consensus target price of $2.50 for the company and are anticipating that the company will post ($0.11) EPS for the current quarter, according to Zacks. Zacks has also assigned SenesTech an industry rank of 180 out of 255 based on the ratings given to related companies.

SNES has been the subject of several research analyst reports. ValuEngine raised SenesTech from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd. Zacks Investment Research raised SenesTech from a “sell” rating to a “hold” rating in a research note on Wednesday, July 25th.

A number of hedge funds have recently modified their holdings of SNES. Bank of Montreal Can bought a new stake in SenesTech during the second quarter worth about $131,000. CVI Holdings LLC bought a new stake in SenesTech during the first quarter worth about $262,000. Finally, Sabby Management LLC lifted its stake in SenesTech by 81.9% during the first quarter. Sabby Management LLC now owns 794,740 shares of the company’s stock worth $405,000 after purchasing an additional 357,877 shares during the last quarter. 8.11% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ SNES traded down $0.02 during mid-day trading on Thursday, hitting $0.70. The company had a trading volume of 171,347 shares, compared to its average volume of 336,637. SenesTech has a 1 year low of $0.30 and a 1 year high of $3.87. The company has a current ratio of 5.05, a quick ratio of 4.07 and a debt-to-equity ratio of 0.05.

SenesTech (NASDAQ:SNES) last posted its quarterly earnings data on Monday, August 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.12). The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.40 million. SenesTech had a negative net margin of 13,362.22% and a negative return on equity of 214.75%. sell-side analysts forecast that SenesTech will post -0.61 earnings per share for the current fiscal year.

SenesTech Company Profile

SenesTech, Inc develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.

Read More: Do You Need a Fiduciary?

Get a free copy of the Zacks research report on SenesTech (SNES)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with's FREE daily email newsletter.

Leave a Reply